The cardioprotective actions of hydrogen sulfide in acute myocardial infarction and heart failure.

David J. Polhemus, LSU Health Sciences Center
John Calvert, Emory University
Javed Butler, Emory University
David J. Lefer, LSU Health Sciences Center

Journal Title: Scientifica
Volume: Volume 2014
Publisher: Hindawi Publishing Corporation | 2014-06-22, Pages 768607-768607
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1155/2014/768607
Permanent URL: https://pid.emory.edu/ark:/25593/s2tz8

Final published version: http://dx.doi.org/10.1155/2014/768607

Copyright information:
© 2014 David J. Polhemus et al.
This is an Open Access work distributed under the terms of the Creative Commons Attribution 3.0 Unported License (http://creativecommons.org/licenses/by/3.0/).
The Cardioprotective Actions of Hydrogen Sulfide in Acute Myocardial Infarction and Heart Failure

David J. Polhemus, 1 John W. Calvert, 2 Javed Butler, 3 and David J. Lefer 1

1 Department of Pharmacology and Experimental Therapeutics and Cardiovascular Center of Excellence, LSU Health Sciences Center, New Orleans, LA 70112, USA
2 Department of Surgery, Emory University School of Medicine, Atlanta, GA 30322, USA
3 Department of Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA

Correspondence should be addressed to David J. Lefer; dlefe1@lsuhsc.edu

Received 27 February 2014; Revised 30 April 2014; Accepted 16 May 2014; Published 22 June 2014

Academic Editor: Gisele Zapata-Sudo

Copyright © 2014 David J. Polhemus et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

It has now become universally accepted that hydrogen sulfide (H₂S), previously considered only as a lethal toxin, has robust cytoprotective actions in multiple organ systems. The diverse signaling profile of H₂S impacts multiple pathways to exert cytoprotective actions in a number of pathological states. This paper will review the recently described cardioprotective actions of hydrogen sulfide in both myocardial ischemia/reperfusion injury and congestive heart failure.

1. Introduction

Hydrogen sulfide (H₂S) has long been viewed simply as a toxic gas with an odorous smell. Its dangerous properties were recognized as far back as the 18th Century when cesspit workers exposed to high environmental levels of H₂S developed eye inflammation and bacterial infection [1] (Figure 1). More recently, however, H₂S was discovered to exist endogenously and has emerged as an omnipotent signaling molecule, specifically in the cardiovascular system [2–7]. Several years ago, cardiovascular researchers largely focused on the other gaseous signaling molecules, nitric oxide (NO) and carbon dioxide (CO). Consensus formed that NO and CO based therapies protect the brain, heart, and circulation against a number of cardiovascular diseases [8–14]. Because endogenously produced H₂S is a gaseous signaling molecule capable of regulating physiological processes (similar to NO and CO), we investigated its potential role as a cardioprotective agent. Our group has shown specifically that H₂S protects against myocardial ischemia/reperfusion (MI/R) injury and preserves cardiac function following the onset of heart failure in various preclinical model systems.

2. Endogenous Synthesis of Hydrogen Sulfide in Mammals

Experimental studies reveal that H₂S is produced at nano- to micromolar levels both enzymatically and nonenzymatically [15]. The continuous enzymatic production is critical due to the extremely short biological half-life of the molecule (estimated to be between seconds to minutes) [16, 17]. Nonenzymatic H₂S can form via the reduction of thiol-containing molecules when H₂S is released from sulfur stores such as sulfane sulfur. Two H₂S producing enzymes are part of the cysteine biosynthesis pathway: cystathionine gamma lyase (CSE) and cystathionine beta synthase (CBS). These enzymes coordinate with L-cysteine to produce H₂S, L-serine, pyruvate, and ammonia [2, 4]. Originally, the endogenous production of H₂S in the brain was attributed to CBS [18]. However, more recently, the third enzyme, 3-mercaptopyruvate sulfurtransferase (3-MST), was reported to manufacture roughly 90% of H₂S in the brain and is largely concentrated in the mitochondria [19]. 3-MST produces H₂S from α-ketoglutarate and L-cysteine via metabolic actions with cysteine aminotransferase and glutamate [19]. The distribution and function of CBS, CSE, and 3-MST under normal
physiological conditions remain controversial and unclear. However, we have found that all 3 enzymes are expressed in the heart [20] and a global genetic deletion of CSE (global CBS and 3MST KO mice have not yet been reported) results in significant reductions in myocardial and circulating H₂S and sulfane sulfur levels [21]. As this field advances, more discoveries will likely unfold and give us more insight into the physiological mechanism of these enzymes.

3. Hydrogen Sulfide and Myocardial Infarction

Myocardial infarction remains a leading cause of mortality worldwide [22]. It is well established that myocardial ischemia/reperfusion (MI/R) injury stimulates tissue destruction and often leads to heart failure [23]. While reperfusion relieves ischemia, it also results in a complex reaction that leads to cell injury caused by inflammation and oxidative damage [24]. In the first study, to establish an in vivo model for MI/R in mice, the left coronary artery (LCA) was transiently ligated and reperfusion followed by removal of the ligating suture [25]. Following 30 minutes of ischemia, mice were administered sodium sulfide (Na₂S) (50 μg/kg) into the left ventricle (LV) lumen. Mice receiving the donor at the time of reperfusion displayed a 72% reduction in infarct size compared to the vehicle treated mice [25]. Cardiac troponin-I (cTnI) evaluation, an additional marker for myocardial injury, also affirmed myocardial preservation in the H₂S treated group. Additionally, LV echocardiographic analysis following 72 hours of reperfusion revealed that H₂S treated mice displayed no increase in post-MI/R LV dimensions (left ventricular end-diastolic dimensions and left ventricular end-systolic dimensions), while the vehicle treated group showed significantly increased wall thickening [25].

A subsequent study examined the impact of genetically modifying an enzyme responsible for much of endogenous H₂S production (CSE) [25]. Using a heavy chain αMHC promoter in coordination with the cystathionine (Cth) gene sequence (responsible for CSE production), a cardiac specific transgene mouse was created to constitutively overexpress the CSE enzyme. These mice had a significantly elevated production rate of H₂S, as expected, and were subjected to a similar MI/R protocol. Following 45 minutes of ischemia and 72 hours of reperfusion, the transgenic mice expressed significantly reduced infarct size compared to the wild-type group. These findings reveal that both exogenous donors and endogenously elevated H₂S serve to protect against ischemia-reperfusion injury in the murine heart.

The mechanisms by which H₂S protected against MI/R injury, we found, are through preservation of mitochondrial function, reduction of cardiomyocyte apoptosis, anti-inflammatory responses, and antioxidant effects that limit cell damage and death. Mitochondria are essential for cell survival and energy production. They are unique in that they regulate cell death and apoptosis and maintain oxidative phosphorylation following MI in a manner that helps to preserve myocyte survival [26]. In vitro experiments revealed a dose-dependent reduction in oxygen consumption followed
by a recovery to baseline levels in the H$_2$S treated group [25]. Additionally, H$_2$S at the time of reperfusion preserved function as noted by increases in efficiency of complexes I and II of the electron transport chain. In an ischemia setting, mitochondrial function can be compromised as a result of an increase in reactive oxygen species (ROS), which can lead to uncoupling and increased infarction [27, 28]. High doses of H$_2$S can slow down cellular respiration by inhibiting cytochrome c oxidase, lowering metabolism into a protected, preconditioned state [29]. The inhibition of respiration has been shown to protect against MI/R injury by limiting the generation of ROS species [30, 31].

We also found H$_2$S to have antioxidant properties mediated by Nrf-2 signaling. Nrf-2 is a potent antioxidant transcription factor that can translocate from the cytosol to the nucleus to induce various antioxidant proteins. This protein promotes oxidant defenses and reduces oxidative stress. When mice were treated with a long acting H$_2$S donor, diallyl trisulfide (DATS), following acute MI, Nrf-2 translocated from the cytosol to the nucleus while overall levels of Nrf2 remained constant within the cell [32]. Additional studies further demonstrate the downstream signaling of Nrf2 induced by H$_2$S to promote antioxidant defenses [33-36]. These cardioprotective actions, we believed, would also prove to be protective in other heart diseases. We then investigated H$_2$S in heart failure.

4. Hydrogen Sulfide and Heart Failure

Heart failure is the heart's inability to sufficiently supply blood to meet the needs of the body. In the United States, it has become the most common discharge diagnosis in patients 65 years or older and treatments remain insufficient [37, 38]. Therefore, the investigation of therapeutic options to attenuate cardiac dysfunction in heart failure remains clinically relevant and critical.

Our group found that heart failure patients have marked reductions in circulating H$_2$S levels compared to age matched controls (Figure 2). In a recent study, Peter et al. reported elevated plasma H$_2$S levels in patients with vascular disease [39]. The results in this study do not contradict our findings of reduced H$_2$S in heart failure patients. The patient profiles in the two studies are dissimilar and do not represent similar disease states. The heart failure patients analyzed in the current study suffer from severe end stage cardiomyopathy with reduced heart function [40]. Conversely, patients in the recent study suffered from coronary or peripheral arterial disease. We do not take these findings as conflicting but acknowledge that changes in H$_2$S are dependent on numerous factors, such as the type of cardiovascular disease (i.e., coronary heart disease or heart failure). The discovery of H$_2$S deficiency in heart failure patients led to our exploration of H$_2$S therapy for the treatment of heart failure. In our preliminary study to create a heart failure in the murine heart, transverse aortic constriction (TAC) between the brachiocephalic trunk and the left carotid artery produced a hypertrophic, pressure overload induced model [20]. We observed greater than a 60% decrease in both myocardial and circulating H$_2$S levels following TAC compared to naïve mice. This finding was in accordance with our discovery that heart failure patients have a H$_2$S deficiency. We next compared mice devoid of the CSE enzyme to wild type mice following TAC. CSE KO mice exhibited significantly greater cardiac dilatation and exacerbated dysfunction than wild-type mice, indicating the demand of H$_2$S to protect against pressure overload heart failure. We then examined H$_2$S therapy in the setting of heart failure. SG-1002, an H$_2$S donor, was infused in the chow and was continuously administered throughout the study beginning the day of aortic constriction. Interestingly, the therapy prevented cardiac dilatation and preserved LV function throughout the 12-week course of the study. Morphological analysis after TAC revealed that H$_2$S treated mice had minor cardiac enlargement compared to the vehicle group, indicating reduced hypertrophy. Similar analysis displayed less pulmonary edema in the H$_2$S treated group.
In addition to its antioxidant actions and mitochondrial protection, H$_2$S appears to promote angiogenic responses and inhibit fibrosis during heart failure. Histological analysis revealed that left ventricular intermuscular and perivascular fibrosis were significantly attenuated at 6 weeks following TAC in the H$_2$S treated group [41]. Mice treated with H$_2$S donors in the setting of heart failure also displayed significantly greater VEGF (a potent angiogenic cytokine) and CD31$^+$ (an endothelial cell marker) expression in the myocardium.

Other studies have concurred that the downregulation of H$_2$S is involved in the pathogenesis of cardiomyopathy induced by Adriamycin [42] and myocardial injury induced by isoproterenol [43]. In these studies, myocardial injury resulted in decreased CSE activity, reduced heart and plasma H$_2$S levels, and increased oxidative stress. However, total CSE gene expression was elevated in the heart failure models. These findings were in accordance with our pressure overload induced heart failure model where we observed a robust CSE protein expression but a significant decrease in blood and myocardial H$_2$S levels compared to sham mice [20].

5. Mechanisms of Cardioprotection

Many of the cardioprotective mechanisms resulting from H$_2$S therapy in acute MI and congestive heart failure are similar (Figure 3). For example, H$_2$S promotes the translocation of the nuclear transcription factor, Nrf2, from the cytosol to the nucleus resulting in the subsequent expression of numerous detoxifying genes such as heme oxygenase 1 (HO-1), superoxide dismutase, and catalase [44, 45]. In addition, H$_2$S protects cells against oxidative stress by increasing glutathione levels in a cysteine dependent manner [46]. Although H$_2$S acts independently to activate antioxidant and prosurvival signals, crosstalk between H$_2$S and NO may also play an important role [21, 47]. H$_2$S is known to activate endothelial nitric oxide synthase (eNOS) and augment NO bioavailability [20, 41]. NO is well established as a signaling molecule with antioxidant characteristics [48, 49] and may enhance these protective signaling actions.

H$_2$S also plays a critical role in the protection of mitochondria during ischemic states in a manner that significantly attenuates cell death and apoptosis [26, 50]. Following MI/R injury, H$_2$S treated mice exhibited diminished activation of caspase-3 and a decreased TUNEL positive nuclei count [25]. H$_2$S also promotes antiapoptotic signaling pathways by altering p38, Erk 1/2, and PI3K expression [51, 52]. Acutely, H$_2$S attenuates mitochondrial respiration to induce a "suspended-animation-" like state and reduces cellular respiration and oxygen demand [29, 53]. Establishing this state can preserve mitochondrial function by reducing oxidative stress and mitigating apoptotic signaling. This renders H$_2$S particularly protective against myocyte injury in settings such as acute MI/R.

One of the earliest proposed benefits of H$_2$S as a physiological modulator on the vasculature is its ability to
6. Future Directions

A number of laboratories have clearly demonstrated the cardioprotective actions of H\textsubscript{2}S in both acute myocardial infarction and heart failure [59–62]. The mechanisms responsible for these protective effects include the downregulation of oxidative stress responses, modulation of mitochondrial respiration, attenuation of apoptosis, and increasing vascular growth and angiogenesis. H\textsubscript{2}S is known to activate multiple and diverse pathways simultaneously and exhibits crosstalk with the NO and CO signal pathways to amplify a cytoprotection response. In addition, H\textsubscript{2}S freely circulates throughout the body, diffuses across cellular membranes, and acts on multiple cellular targets [63]. Furthermore, the actions of H\textsubscript{2}S are not limited to the heart muscle alone but can impact the entire cardiovascular system including blood vessels [7]. In fact, with this field only recently developing, there are tremendous opportunities for further discovery relating to H\textsubscript{2}S physiology, pharmacology, and pathology. Recent experimental data provide evidence that H\textsubscript{2}S can prevent atherosclerosis and promotes angiogenesis in the peripheral arteries [55, 64]. This may prove beneficial when treating vascular diseases that demand collateral vessel growth such as peripheral artery disease (PAD) and critical limb ischemia (CLI). Recently, several groups have reported that H\textsubscript{2}S also plays a role in pulmonary hypertension and acute lung injury [65, 66]. Although H\textsubscript{2}S does not have the potent vasodilation capabilities of NO, the combination of vascular smooth muscle relaxation and potent antioxidant properties may be the source for protection against pulmonary hypoxia and hypertension. In both the liver and the kidneys, H\textsubscript{2}S is a protective preconditioning agent against ischemia/reperfusion injury [67, 68]. Similarly to myocardial ischemia/reperfusion protection, H\textsubscript{2}S protects by its ability to mitigate apoptosis and modulate oxidative stress.

Discovering the most effective H\textsubscript{2}S donors is also a challenge facing the field. Drugs such as NaHS, Na\textsubscript{2}S, and GYY4137 are all effective H\textsubscript{2}S donors, but their rapid half-life renders them less effective for treating chronic diseases. The slow releasing polysulfides deliver a more gradual release of H\textsubscript{2}S [32]. Other proposed sulfide-modulating agents such as S-propargyl-cysteine do not substantially raise H\textsubscript{2}S levels in vivo [69]. Dietary formulations, such as SG-1002, can be used as medical foods to replenish an H\textsubscript{2}S deficiency that may occur from diseases such as heart failure. Because of the short half-life of H\textsubscript{2}S (estimated to be between seconds and minutes [17, 70]), developing a drug with specific on-site (organ or organelle specific) delivery would also be beneficial.

Following in the footsteps of nitric oxide and carbon monoxide, hydrogen sulfide is rapidly emerging as a critical cardiovascular signaling molecule. Although the complete actions of this gas remain under investigation, the therapeutic options relating to cardiovascular disease are extremely promising. The coming years or research will dictate the means of utilizing this molecule effectively against various cardiovascular disease states.

Conflict of Interests

David J. Lefer is a founder of the company Sulfagenix and has significant stock in Sulfagenix. David J. Lefer is also the Chief Scientific Officer for Sulfagenix. Sulfagenix is currently developing hydrogen sulfide (H\textsubscript{2}S) based therapeutics for the treatment of cardiovascular and other diseases. There are no other conflicts.

Acknowledgments

The authors would like to thank The Atlanta Cardiomyopathy Consortium (TACC) for generously providing blood samples from heart failure patients for the measurement of hydrogen sulfide. This work was supported by Grants from the National Heart, Lung, and Blood Institute (National Institutes of Health; R01 HL092141, R01 HL093579, 1U24 HL 094373, and IP20 HL113452 to David J. Lefer). The authors are also grateful for the generous funding support from TEVA USA Scholars Program and the LSU Medical School Alumni Association.

References


[70] M. A. Insko, T. L. Deckwerth, P. Hill, C. F. Tombs, and C. Szabo, “Detection of exhaled hydrogen sulphide gas in rats exposed to...


